» Articles » PMID: 15126372

Disruption of Cancer Cell Replication by Alternating Electric Fields

Overview
Journal Cancer Res
Specialty Oncology
Date 2004 May 6
PMID 15126372
Citations 279
Authors
Affiliations
Soon will be listed here.
Abstract

Low-intensity, intermediate-frequency (100-300 kHz), alternating electric fields, delivered by means of insulated electrodes, were found to have a profound inhibitory effect on the growth rate of a variety of human and rodent tumor cell lines (Patricia C, U-118, U-87, H-1299, MDA231, PC3, B16F1, F-98, C-6, RG2, and CT-26) and malignant tumors in animals. This effect, shown to be nonthermal, selectively affects dividing cells while quiescent cells are left intact. These fields act in two modes: arrest of cell proliferation and destruction of cells while undergoing division. Both effects are demonstrated when such fields are applied for 24 h to cells undergoing mitosis that is oriented roughly along the field direction. The first mode of action is manifested by interference with the proper formation of the mitotic spindle, whereas the second results in rapid disintegration of the dividing cells. Both effects, which are frequency dependent, are consistent with the computed directional forces exerted by these specific fields on charges and dipoles within the dividing cells. In vivo treatment of tumors in C57BL/6 and BALB/c mice (B16F1 and CT-26 syngeneic tumor models, respectively), resulted in significant slowing of tumor growth and extensive destruction of tumor cells within 3-6 days. These findings demonstrate the potential applicability of the described electric fields as a novel therapeutic modality for malignant tumors.

Citing Articles

Optimized Methods to Quantify Tumor Treating Fields (TTFields)-Induced Permeabilization of Glioblastoma Cell Membranes.

Martinez-Paniagua M, Khan S, Henning N, Konagalla S, Patel C Methods Protoc. 2025; 8(1).

PMID: 39997634 PMC: 11858626. DOI: 10.3390/mps8010010.


Tumor-treating fields and concurrent cisplatin: an demonstration of efficacy in triple-negative breast cancer.

Smothers A, Beasley M, Warren H, Kegel O, Edenfield W, OConnell J Am J Cancer Res. 2025; 15(1):322-330.

PMID: 39949927 PMC: 11815381. DOI: 10.62347/LXJH5896.


Advancing cancer therapy with custom-built alternating electric field devices.

Jobson I, Vo N, Kujawinski E, Denning C, Stolnik S, Chauhan V Bioelectron Med. 2025; 11(1):2.

PMID: 39881409 PMC: 11780810. DOI: 10.1186/s42234-024-00164-3.


Origins of the Superiority of Oscillating Electric Fields for Disrupting Senile Plaques: Insights from the 7-Residue Fragment and the Full-length Aβ-42 Peptide.

Kalita S, Danovich D, Shaik S J Am Chem Soc. 2025; 147(3):2626-2641.

PMID: 39772489 PMC: 11760182. DOI: 10.1021/jacs.4c14791.


Advancements and challenges in brain cancer therapeutics.

Bai F, Deng Y, Li L, Lv M, Razzokov J, Xu Q Exploration (Beijing). 2024; 4(6):20230177.

PMID: 39713205 PMC: 11655316. DOI: 10.1002/EXP.20230177.